Data updated: Mar 10, 2026
KYNAMRO
MIPOMERSEN SODIUM
Approved 2013-01-29
1
Indication
--
Phase 3 Trials
13
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2013-01-29
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SOLUTION
KYNAMRO Approval History
Loading approval history...
What KYNAMRO Treats
1 FDA approvalsOriginally approved for its first indication in 2013 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KYNAMRO FDA Label Details
ProKYNAMRO Patents & Exclusivity
Latest Patent: Jan 2027
Patents (1 active)
US7511131
Expires Jan 29, 2027
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.